VSTM : Summary for Verastem, Inc. - Yahoo Finance

U.S. Markets open in 5 hrs 47 mins

Verastem, Inc. (VSTM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.07-0.05 (-4.46%)
At close: 4:00 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close1.12
Bid0.00 x
Ask0.00 x
Day's Range1.07 - 1.16
52 Week Range1.05 - 2.06
Avg. Volume157,107
Market Cap39.58M
PE Ratio (TTM)-1.08
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire6 hours ago

    Verastem Presents Phase 2 DYNAMO® Clinical Data at ASH 2016 Annual Meeting

    Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced the presentation of results from the DYNAMO® study, a Phase 2 clinical trial evaluating the safety and efficacy of duvelisib in patients with indolent non-Hodgkin lymphoma that is double refractory to both rituximab and chemotherapy, at the American Society of Hematology 2016 Annual Meeting held December 3-6, ...

  • Zacks25 days ago

    Infinity (INFI) Reports Narrower-than-Expected Loss in Q3

    Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 39 cents per share in third-quarter 2016.

  • Associated Press28 days ago

    Verastem reports 3Q loss

    On a per-share basis, the Needham, Massachusetts-based company said it had a loss of 21 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...